# Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS

> **NCT01995981** · — · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 22 (actual)

## Conditions studied

- Sarcoma, Soft Tissue

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT01995981
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2017-11-10
- **Final completion:** 2017-11-10
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01995981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01995981, "Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01995981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*